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Summary
Objective: Although plasma adiponectin levels may be a marker for the severity of
coronary artery disease (CAD) and can help to predict future cardiovascular events
in patients with CAD, the signiﬁcance of changes in plasma adiponectin levels after
the implantation of stents in patients with stable angina is unclear.
Methods: The subjects included 32 consecutive patients with stable angina who had
undergone successful coronary stenting [bare metal stent (BMS, n = 16) or sirolimus-
eluting stent (SES, n = 16)]. Blood sampling was performed at baseline, and at 24 h,
48 h, 14 days and 6 months after stenting.
Results: Plasma high-sensitivity C-reactive protein (hs-CRP) levels at baseline
(0.16± 0.15mg/dl) were signiﬁcantly increased at 24 h (0.36± 0.45mg/dl, p = 0.011)
and 48 h (1.01± 1.01mg/dl, p < 0.001), and plasma adiponectin levels at baseline
(6.7± 4.2g/ml) were signiﬁcantly decreased at 24 h (6.1± 4.2g/ml, p = 0.019)
and 48 h (6.2± 4.9g/ml, p = 0.010) in all subjects. Although there were no sig-
niﬁcant differences in changes in plasma hs-CRP and adiponectin levels between
BMS and SES groups during the study period, BMS group (6.5± 0.9g/ml at base-
line) showed a signiﬁcant reduction of plasma adiponectin at 48 h (5.8± 1.1g/ml,
p = 0.022) and 6 months after stenting (4.7± 2.3g/ml, p = 0.011). Percent diam-
eter stenosis (%DS) at 6 months after stenting was negatively correlated with
changes in the plasma adiponectin levels within 6 months [adiponectin (6
months−baseline)]. In addition, multiple logistic regression analysis revealed
hs after stenting was most closely correlated with
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Conclusions: Coronary stenting may decrease circulating adiponectin in association
with an inﬂammatory response. The changes in plasma levels of adiponectin after
stenting may also be a predictor of coronary restenosis in patients with CAD.
e of Cardiology. Published by Elsevier Ireland Ltd. All rights
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function were excluded from the study. Patients
with total cholesterol (TC) greater than 220mg/dl
or triglyceride (TG) greater than 150mg/dl were© 2008 Japanese Colleg
reserved.
Introduction
Adiponectin is an adipokine that is predominantly
synthesized in adipose tissue [1]. It is paradoxically
reduced in obesity and has been found to be a major
modulator of insulin resistance and to be related to
metabolic syndrome.
Metabolic syndrome, which consists of a cluster-
ing of cardiovascular risk factors, such as abdominal
obesity, insulin resistance, dyslipidemia and hyper-
tension, is associated with increased cardiovascular
morbidity and mortality [2]. Since plasma lev-
els of adiponectin are signiﬁcantly decreased in
patients with coronary artery disease (CAD) [3],
hypoadiponectinemia is also considered to be an
independent risk factor for CAD. Furthermore,
plasma concentrations of adiponectin in patients
with acute coronary syndrome (ACS) were signif-
icantly lower than those in patients with stable
angina pectoris and in the control group [4].
Plasma adiponectin levels are signiﬁcantly asso-
ciated with coronary lesion complexity in men
with CAD, and low adiponectin levels may also
contribute to coronary plaque vulnerability [5].
Although these numerous reports indicate that
plasma adiponectin levels are a marker for the
severity of CAD and can predict future cardiovas-
cular events in patients with CAD, the signiﬁcance
of changes in plasma adiponectin levels after the
implantation of stents in patients with CAD is
unclear. In addition, Kochiadakis et al. reported
that there were differences in inﬂammatory acti-
vation between the implantation of a bare metal
stent (BMS) and sirolimus-eluting stent (SES) [6]. It
is possible that the time course of plasma levels
of adiponectin is also different between BMS and
SES.
Adiponectin is an anti-inﬂammatory compound
through nuclear factor-B [7]. It also downregulates
adhesion molecule expression on endothelial cells
[8] and enhances lipid clearance [9]. Since adhe-
sion molecule expression and the C-reactive protein
(CRP) concentration are increased after coronary
stenting [6], adiponectin could decrease inﬂam-
mation and adhesion molecule expression. These
rescue mechanisms induced by adiponectin may
also protect against coronary restenosis.
d
s
1
hTherefore, we analyzed plasma adiponectin lev-
ls after the implantation of stents in patients
ith stable angina and compared the differences
etween a bare metal stent and sirolimus-eluting
tent.
aterials and methods
ubjects and design
he subjects included 32 consecutive patients with
table angina who had a de novo target lesion
hat was suitable for implanting (stent diameter
s more than 2.5mm) either a BMS (n = 16) or a
ES (n = 16) by the judgment of the operator. All
atients received aspirin (100mg/day) and ticlopi-
ine (200mg/day) and showed signiﬁcant coronary
tenosis (>50% luminal narrowing) as determined
y coronary angiography. Direct stenting was
ot allowed. Follow-up coronary angiography was
erformed at 6 months. After successful pre-
ilation of the target lesion, patients underwent
mplantation of the stent. Procedural success was
eﬁned as successful implantation of the study
evice, a ﬁnal vessel diameter stenosis <50%, and
reedom from in-hospital major adverse cardiac
vents, deﬁned as death, myocardial infarction,
nd emergency coronary artery bypass grafting.
e assessed the absolute changes in plasma lev-
ls of adiponectin, high-sensitivity CRP (hs-CRP)
nd stenosis as measured by quantitative coro-
ary angiography (QCA) between post-stent and
ollow-up angiograms at 6 months after stenting.
here was no cardiac event in any of the patients
hroughout the study. The ethics committee of
ukuoka University Hospital approved this study and
ritten informed consent was obtained from each
atient.
Patients with vascular disease or hepatic dys-iagnosed as hyperlipidemia (HL). Patients with
ystolic (diastolic) blood pressure greater than
40mmHg (90mmHg) or who were under anti-
ypertensive treatment were considered to have
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rank test. Relationships between variables were
tested by Pearson and Spearman correlations. A
value of p < 0.05 was considered signiﬁcant. Multi-
ple logistic regression analysis was performed for
independent variables that were related to QCA
parameters.
Results
Patient characteristics
Patient characteristics [age, sex, body mass
index, the incidences of HT, DM, HL and hyper-
uricemia (HU) or medications (angiotensin convert-
ing enzyme inhibitor, angiotensin receptor blocker,
calcium channel blocker, -blocker, etc.)] in all
subjects are shown in Table 1. There were no
differences in any of the patient characteris-
tics between the BMS and SES groups (data not
shown).
Table 1 Baseline patients characteristics
Variable
Age (years) 63.3± 11.4
Male, n (%) 3 29 (90.1)
BMI (kg/m2) 24.2± 2.9
History, n (%)
HT 22 (68.8)
DM 18 (56.3)
Hyperlipidemia 18 (56.3)
Hyperuricemia 10 (31.3)
Current smoker 20 (62.5)
Preprocedural laboratory
HbAlc (%) 6.3± 1.7
TC (mg/dl) 180.3± 30.3
TG (mg/dl) 126.7± 68.5
HDL-C (mg/dl) 44.5± 11.5
LDL-C (mg/dl) 110.4± 25.0
UA (mg/dl) 5.4± 1.4
Preprocedural medications, n (%)
ACEI 3 (9.4)
ARB 18 (56.3)
CCB 16 (50.0)
-Blocker 5 (15.6)
Diuretics 6 (18.8)
ISDN 10 (31.3)
Statin 14 (43.8)
BMI, body mass index; HT, hypertension; DM, diabetes
mellitus; TC, total cholesterol; TG, triglyceride; HDL-C,igniﬁcance of changes in plasma adiponectin conc
ypertension (HT). Patients who were being treated
or diabetes mellitus (DM) or who had a fasting
lucose concentration greater than 126mg/dl were
onsidered to have DM. Otherwise, the results of
75-g oral glucose tolerance test were used to
iagnose DM. None of the patients was receiving
ormone replacement therapy.
lood sampling
lood sampling was performed at ﬁve points:
t baseline and at 24 h, 48 h, 14 days and 6
onths after stenting. Samples were examined
ith regard to plasma adiponectin, hs-CRP and
ipid proﬁle. The concentrations of adiponectin
n plasma were determined in duplicate by an
diponectin ELISA kit (Otsuka Pharmaceutical Co.
td., Tokushima, Japan) according to the man-
facturer’s instructions. At our laboratory, the
ntra- and inter-assay coefﬁcients of variation were
ach 5%.
oronary angiography
oronary angiograms were divided into 15 segments
ccording to the classiﬁcation of the Ameri-
an Heart Association Grading Committee. All
ngiograms were analyzed qualitatively and quan-
itatively at the angiographic core lab at Fukuoka
niversity Hospital. A lab member carried out
he analysis blindly without being informed of
he kind of stent. QCA was performed on all
ualifying angiograms and was conducted using
ME (MEDIS, The Netherlands) at pre (immedi-
tely after the procedure) and at the 6-month
ollow-up. Binary restenosis was deﬁned as >50%
iameter stenosis (DS). QCA analysis included stent
easurement [minimum lumen diameter (MLD)
onﬁrmed within the proximal and distal stent bor-
ers] and systematic analysis of the proximal and
istal stent edges. The observers at the angio-
raphic core lab were blind to the blood sample
ata.
tatistical analysis
tatistical analysis was performed using StatView
-5.0 (SAS Institute Inc., Cary, NC). Data are shown
s the mean± S.D. Categorical and continuous vari-
bles in the SES and BMS groups were compared
y a chi-square analysis and analysis of variance,
espectively. In addition, differences in continu-
us variables (hs-CRP and adiponectin) between
wo groups were examined by Mann—Whitney U-
est. The changes in continuous variables during the
tudy period were examined by Wilcoxon signed-
high-density lipoprotein cholesterol; LDL-C, low-density
lipoprotein cholesterol; UA, uric acid; ACEI, angiotensin
converting enzyme inhibitor; ARB, angiotensin II receptor
blocker; CCB, calcium channel blocker; ISDN, isosorbide
dinitrate.
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Table 2 Angiographic characteristics and quantitative coronary angiographic analysis
All BMS group SES group
Pre-procedure
Number of vessels (n)
1VD/2VD/3VD 19/8/5 12/2/2 7/6/3
Culprit coronary artery (n)
RCA/LAD/LCx 9/14/9 5/7/4 4/7/5
Lesion type B2/C, n (%) 19 (54) 7 (44) 12 (75)
Reference (mm) 3.13± 0.12 3.26± 0.19 3.04± 0.15
MLD (mm) 0.92± 0.07 0.93± 0.09 0.91± 0.11
%DS 69.9± 2.2 69.1± 2.6 63.9± 3.9
Final procedure
Stent length (mm) 20± 7 20± 5 21± 3
Stent diameter (mm) 3.3± 0.7 3.4± 0.5 3.1± 0.3
Maximal inﬂation pressure (atm) 14± 2 13± 2 15± 2
Reference (mm) 3.12± 0.09 3.20± 0.11 3.09± 0.12
MLD (mm) 2.14± 0.06 2.21± 0.08 2.08± 0.10
%DS 26.0± 1.8 25.3± 2.4 26.3± 2.7
Acute lumen gain (mm) 1.22± 0.07 1.27± 0.11 1.16± 0.08
6 months follow-up
Reference (mm) 3.19± 0.10 3.18± 0.14 3.19± 0.14
MDL (mm) 1.87± 0.10 1.66± 0.15 2.26± 0.10*
%DS 37.1± 2.7 44.9± 3.4 23.1± 0.1*
In-stent lumen loss (mm) 0.27± 0.10 0.55± 0.15 −0.18± 0.07*
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left circumﬂex artery; MLD, minimum lumen diameter; DS, dia
Angiographic and stent implantation
procedure characteristics and QCA analysis
Angiographic and stent implantation procedure
characteristics are shown in Table 2. Sixteen
patients (BMS group) received a Multi-link Zeta
stent (Abbott Vascular, USA) (n = 7), Express 2 stent
(Boston Scientiﬁc, USA) (n = 5), Driver stent (Good-
man, USA) (n = 2) or Duraﬂex stent (Medtronic, USA)
(n = 2), while all 16 patients in the SES group were
given a Cypher stent (Johnson & Johnson, USA).
Based on QCA results at 6 months (Table 2), %DS
and in-stent late lumen loss in the SES group were
signiﬁcantly lower than those in the BMS group.
Therefore, MLD at 6 months in the SES group was
signiﬁcantly greater than that in the BMS group.
Consequently, the number of patients with in-stent
restenosis and target lesion revascularization in the
SES group (n = 1 and n = 1, respectively) were lower
than those in the BMS group (n = 4 and n = 2, respec-
tively).Plasma levels of hs-CRP and adiponectin
Time-course changes in plasma levels of hs-
CRP and adiponectin after stenting are shown
in Fig. 1a and b, respectively. Plasma hs-CRP
l
r
l
i
yoronary artery; LAD, left anterior descending artery; LCx,
r stenosis. *p < 0.01 versus BMS group.
evels at baseline (0.16± 0.15mg/dl) were sig-
iﬁcantly increased at 24 h (0.36± 0.45mg/dl,
= 0.011) and 48 h (1.01± 1.01mg/dl, p < 0.001),
nd plasma adiponectin levels at baseline
6.7± 4.2g/ml) were signiﬁcantly decreased
t 24 h (6.1± 4.2g/ml, p = 0.019) and 48 h
6.2± 4.9g/ml, p = 0.010) in all subjects.
lthough there were no signiﬁcant differences
n changes in plasma hs-CRP and adiponectin
evels between BMS and SES groups during the
tudy period, BMS group (6.5± 0.9g/ml at base-
ine) showed a signiﬁcant reduction of plasma
diponectin at 48 h (5.8± 1.1g/ml, p = 0.022)
nd 6 months after stenting (4.7± 2.3g/ml,
= 0.011).
orrelation between changes in plasma
diponectin levels and QCA parameters
correlation analysis showed that plasma levels
f adiponectin at 6 months were positively corre-
ated with MLD at 6 months (n = 32, y = 1.59 + 0.05x,
= 0.351, p = 0.04) (Fig. 2a), and changes in plasma
evels of adiponectin within 6 months were pos-
tively correlated with %DS at 6 months (n = 32,
= 33.9−2.9x, r = 0.411, p = 0.02) (Fig. 2b). To fur-
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Figure 1 (a) Time course of hs-CRP in all subjects (gray
square), and in the BMS (closed circle) and SES (open cir-
cle) groups. *p < 0.05 versus at baseline in all subjects.
#p < 0.05 versus at baseline in the BMS group. tp < 0.05 ver-
sus at baseline in the SES group. (b) Time course of plasma
adiponectin in all subjects (gray square), and in the BMS
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Figure 2 (a) Correlation between plasma adiponectin
at 6 months after stenting and MLD at 6 months. n = 32,
y = 0.05x + 1.59, r = 0.351, p = 0.04. Open and closed
circles indicate BMS and DES groups, respectively. (b) Cor-
relation between changes in plasma adiponectin between
baseline and at 6 months after stenting (adiponectin)
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tclosed circle) and SES (open circle) groups. *p < 0.05 ver-
us at baseline in all subjects. #p < 0.05 versus at baseline
n the BMS group.
her analyze the signiﬁcance of plasma levels
f adiponectin after stenting, multiple logistic
egression analysis was performed for the inde-
endent variables (changes in plasma levels of
diponectin and hs-CRP within 24 h, 48 h, 14 days
nd 6 months after stenting) that were related
o %DS at 6 months. The analysis revealed that
DS at 6 months was most closely correlated with
hanges in plasma levels of adiponectin within 6
onths (standard regression coefﬁcient =−0.484,
= 0.031) after adjusting for age, sex and BMI.
iscussionn this study, we demonstrated that the changes in
lasma levels of adiponectin between baseline and
months (late stage) after stenting may predict
oronary restenosis in patients with CAD. Coronary
c
p
a
dnd %DS at 6 months. n = 32, y =−2.9x + 33.9, r = 0.411,
= 0.02. Open and closed circles indicate BMS and DES
roups, respectively.
tenting may decrease circulating adiponectin at
4—48 h (early stage) after stenting and might be
ssociated with a stenting-induced inﬂammatory
esponse.
Although it has been reported that the reduction
f plasma adiponectin during the time course of
yocardial infarction was signiﬁcantly correlated
ith the plasma CRP concentration immediately
fter the onset of AMI [10], this study is the ﬁrst
o show the time course of the plasma adiponectin
oncentration after stenting in patients with CAD.
ojima et al. suggested that strong inﬂamma-
ory activity in vulnerable coronary plaque may
nduce a reduction of plasma adiponectin for up
o 72 h [10]. A decrease in the plasma adiponectin
oncentration will accelerate the inﬂammatory
rocess. Although our results also indicate that
stenting-induced inﬂammatory response may
ecrease plasma adiponectin at an early stage after
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stenting, the plasma levels do not predict coronary
restenosis at a late stage after stenting. Changes
in plasma levels of adiponectin within 6 months
after stenting may be a predictor in the severity
of coronary restenosis in patients with CAD.
Another issue in this study is that the BMS group,
but not SES group, showed a signiﬁcant reduc-
tion of plasma adiponectin at 48 h after stenting.
Although rapamycin is known to attenuate vascu-
lar wall inﬂammation at 21 days after angioplasty
in a human organ culture model [11], it has been
unclear whether SES implantation can induce an
anti-inﬂammatory response at 48 h as in this study.
While our experiments were in progress, Kochi-
adakis et al. reported that SES implantation was
associated with a lower CRP elevation than that
with BMS implantation [9]. In this study, there
were no differences in the elevation of CRP lev-
els at an early stage between the SES and BMS
groups. Although the cause of this discrepancy
is unclear, the more consumption of circulating
adiponectin may have been necessary to induce
anti-inﬂammation in a BMS group based on our
observation. However, further studies are required
to determine the exact mechanism of the combined
effects of adiponectin and rapamycin.
The BMS group also showed a signiﬁcant reduc-
tion of plasma adiponectin at 6 months after
stenting. %DS in the BMS group was signiﬁcantly
greater than that in the SES group because SES itself
could prevent restenosis, since rapamycin inhibits
the proliferation of both smooth muscle cells
and endothelial cells and has anti-inﬂammatory
and anti-thrombotic effects [12]. In the case of
BMS implantation, the consumption of circulating
adiponectin may be needed to prevent coro-
nary restenosis to induce a reduction in adhesion
molecule expression because these molecules have
been shown to be related to the development of
CAD [13], including myocardial infarction [14] and
post-angioplasty restenosis [15].
Plasma adiponectin concentration is regu-
lated by many metabolic factors. Low plasma
adiponectin concentration is found in patients
with metabolic syndrome including obesity and
DM [16]. Adiponectin may also be involved in
the progression of HT. In addition, ACS patients
showed low plasma adiponectin concentration [4].
There were no difference in BMI before and
after 6 months, and no adverse cardiac events
occurred throughout the study. Although statin
[17], angiotensin receptor blocker [18], glitazone
[19] and ﬁbrate [20] signiﬁcantly increased in
plasma adiponectin concentration in humans, no
patients changed the medications throughout the
study.H. Sako et al.
tudy limitations
ur study is based on cardiac catheterization at a
ingle center and thus is limited by a small sample
ize. In addition, since we used angiographic deter-
ination to estimate the progression of coronary
estenosis, some of the patients who were consid-
red to have no progression may actually have had
ome atherosclerotic progression, but were not rec-
gnized. Nonetheless, we believe that our study
hould contribute to understanding the value of
easuring plasma adiponectin in patients with CAD.
onclusions
oronary stenting decreased circulating
diponectin in association with an inﬂamma-
ory response. The changes in plasma levels of
diponectin after stenting within 6 months may
lso predict coronary restenosis in patients with
AD.
cknowledgment
e thank S. Tomita for providing excellent techni-
al assistance.
eferences
[1] Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe
K. Adiponectin and adiponectin receptors in insulin resis-
tance, diabetes, and the metabolic syndrome. J Clin Invest
2006;116:1784—92.
[2] Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo
E, Tuomilehto J, et al. The metabolic syndrome and total
and cardiovascular disease mortality in middle-aged men.
JAMA 2002;288:2709—16.
[3] Kojima S, Funahashi T, Maruyoshi H, Honda O, Sugiyama
S, Kawano H, et al. Levels of the adipocyte-derived
plasma protein, adiponectin, have a close relationship with
atheroma. Thromb Res 2005;115:483—90.
[4] Nakamura Y, Shimada K, Fukuda D, Shimada Y, Ehara S,
Hirose M, et al. Implications of plasma concentrations of
adiponectin in patients with coronary artery disease. Heart
2004;90:528—33.
[5] Otsuka F, Sugiyama S, Kojima S, Maruyoshi H, Funahashi T,
Matsui K, et al. Plasma adiponectin levels are associated
with coronary lesion complexity inmenwith coronary artery
disease. J Am Coll Cardiol 2006;48:1155—62.
[6] Kochiadakis GE, Marketou ME, Arfanakis DA, Sﬁridaki K,
Skalidis EI, Igoumenidis NE, et al. Reduced systemic inﬂam-
matory response to implantation of sirolimus-eluting stents
in patients with stable coronary artery disease. Atheroscle-
rosis 2006;194:433—8.
[7] Ouchi N, Kihara S, Arita Y, Okamaoto Y, Maeda K, Kuriyama
H, et al. Adiponectin, an adipocyte-derived plasma pro-
tein, inhibits endothelial NF-kappaB signaling through
S entr
[
[
[
[
[
[
[
[
[
[igniﬁcance of changes in plasma adiponectin conc
a cAMP-dependent pathway. Circulation 2000;102:1296—
301.
[8] Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y,
et al. Novel modulator for endothelial adhesion molecules:
adipocyte-derived plasma protein adiponectin. Circulation
1999;100:2473—6.
[9] Wang Y, Xu A, Knight C, Xu LY, Cooper GJS. Hydroxylation
and glycosylation of the four conserved lysine residues in
the collagenous domain of adiponectin. Potential role in
themodulation of its insulin-sensitizing activity. J Biol Chem
2002;277:19521—9.
10] Kojima S, Funahashi T, Sakamoto T, Miyamoto S, Spejima H,
Hokamaki J, et al. The variation of plasma concentrations of
a novel, adipocyte derived protein, adiponectin, in patients
with acute myocardial infarction. Heart 2003;89:667—8.
11] Nuhrenberg TG, Voisard R, Fahlisch F, Rudelius M, Braun
J, Gschwend J, et al. Rapamycin attenuates vascular wall
inﬂammation and progenitor cell promoters after angio-
plasty. FASEB J 2005;19:246—8.
12] Parry TJ, Brosius R, Thyagarajan R, Carter D, Argentieri D,
Falotico R. Drug-eluting stents: sirolimus and paclitaxel dif-
ferentially affect cultured cells and injured arteries. Eur J
Pharmacol 2005;524:19—29.
13] Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless
LE. Prospective study of hemostatic factors and incidence
of coronary heart disease: the Atherosclerosis Risk in Com-
munities (ARIC) Study. Circulation 1997;96:1102—8.
14] Tunstall-Pedoe H, Woodward M, Tavendale R, A’Brook R,
McCluskey MK. Comparison of the prediction by 27 differ-
[
Available online at www.ation 23
ent factors of coronary heart disease and death in men and
women of the Scottish Heart Health Study: cohort study.
BMJ 1997;315:722—9.
15] Kamijikkoku S, Murohara T, Tayama S, Matsuyama K, Honda
T, Ando M, et al. Acute myocardial infarction and increased
soluble intercellular adhesion molecule-1: a marker of vas-
cular inﬂammation and a risk of early restenosis? Am Heart
J 1998;136:231—6.
16] Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Taka-
hashi M, et al. Adiponectin as a biomarker of the metabolic
syndrome. Circ J 2004;68:975—81.
17] Furuya R, Odamaki M, Kumagai H, Hayashida A. Impact
of angiotensin II receptor blocker on plasma levels of
adiponectin and advanced oxidation protein products in
peritoneal dialysis patients. Blood Purif 2006;24:445—50.
18] Sugiyama S, Fukushima H, Kugiyama K, Maruyoshi H,
Kojima S, Funahashi T, et al. Pravastatin improved glucose
metabolism associated with increasing plasma adiponectin
in patients with impaired glucose tolerance and coronary
artery disease. Atherosclerosis 2007;194:e43—51.
19] Chu CS, Lee KT, Lee MY, Su HM, Voon WC, Sheu SH, et
al. Effects of rosiglitazone alone and in combination with
atorvastatin on nontraditional markers of cardiovascular
disease in patients with type 2 diabetes mellitus. Am J
Cardiol 2006;97:646—50.
20] Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, et
al. Additive beneﬁcial effects of fenoﬁbrate combined with
atorvastatin in the treatment of combined hyperlipidemia.
J Am Coll Cardiol 2005;45:1649—53.
sciencedirect.com
